Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.30 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.30 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20042480 | 0.95 | KDM4E (0.30) | MAPTMEN1KMT2AKDM4EPABPC1 | |
| SCHEMBL19917220 | 0.89 | — | — | |
| SCHEMBL20042532 | 0.89 | MAPT (0.31) | MAPTMEN1KMT2AKDM4EPABPC1 | |
| SCHEMBL21776016 | 0.89 | MAPT (0.31) | MAPTMEN1KMT2AKDM4EPABPC1 | |
| SCHEMBL19917216 | 0.88 | — | — | |
| SCHEMBL20042503 | 0.87 | MEN1 (0.32) | MAPTMEN1KMT2AKDM4EPABPC1 | |
| SCHEMBL20042501 | 0.87 | MEN1 (0.32) | MAPTMEN1KMT2AKDM4EPABPC1 | |
| SCHEMBL20042485 | 0.87 | MEN1 (0.30) | MEN1KMT2ALMNATNNI3TNNT2 | |
| SCHEMBL20042502 | 0.86 | KDM4E (0.31) | MAPTMEN1KMT2AKDM4EPABPC1 | |
| SCHEMBL20042429 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3523308-B1 | ORGANIC SEMICONDUCTING COMPOUNDS | RAYNERGY TEK INC (TW) | 2023-09-06 | — | — | EP | disclosed |
| US-10991893-B2 | Organic semiconducting compounds | Raynergy Tek Incorporation (TW) | 2021-04-27 | — | — | US | disclosed |
| US-20200052227-A1 | ORGANIC SEMICONDUCTING COMPOUNDS | MERCK PATENT GMBH (DE) | 2020-02-13 | — | — | US | disclosed |
| WO-2018065350-A1 | ORGANIC SEMICONDUCTING COMPOUNDS | MERCK PATENT GMBH (DE) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200052227-A1 | ORGANIC SEMICONDUCTING COMPOUNDS | OCIAD2, OCIAD1, OSTC | MAPT 32/4885MEN1 2805/4885KMT2A 916/4885 |
| US-10991893-B2 | Organic semiconducting compounds | OCIAD2, OCIAD1, OSTC | MAPT 32/4885MEN1 2805/4885KMT2A 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.